BCL9 and neoplasm: Wnt downstream-signaling markers such as Cd44 and Axin2 were reduced in CT26 or MC38 tumors infected with Bcl9-shRNA (supplementary Fig. 1c, d), as well as in tumors treated with hsBCL9CT-24 (compared to vehicle-treated tumors; Fig. 1e), suggesting that BCL9 suppression exhibits robust anti-tumor effects by targeting oncogenic Wnt signaling.